Background: We have previously reported radiation-induced sensitization of canine 38 osteosarcoma (OSA) to natural killer (NK) therapy, including results from a first-in-dog 39 clinical trial. Here, we report correlative analyses of blood and tissue specimens for 40 signals of immune activation in trial subjects. 41 42 Methods: Among 10 dogs treated with palliative radiotherapy (RT) and intra-tumoral 43 adoptive NK transfer, we performed ELISA on serum cytokines, flow cytometry for 44 immune phenotype of PBMCs, and PCR on tumor tissue for immune-related gene 45 expression. We then queried The Cancer Genome Atlas (TCGA) to evaluate the 46 association of cytotoxic/immune-related gene expression with human sarcoma survival. 47 48 Results: Updated survival analysis revealed five 6-month survivors, including one dog 49 who lived 17.9 months. Using feeder line co-culture for NK expansion, we observed 50 maximal activation of dog NK cells on day 17 -19 post isolation with near 100% 51 expression of granzyme B and NKp46 and high cytotoxic function in the injected NK 52 product. Among dogs on trial, we observed a trend for higher baseline serum IL-6 to 53 predict worse lung metastasis-free and overall survival (P=0.08). PCR analysis revealed 54 low absolute gene expression of CD3, CD8, and NKG2D in untreated OSA. Among 55 treated dogs, there was marked heterogeneity in the expression of immune-related genes 56 pre-and post-treatment, but increases in CD3 and CD8 gene expression were higher 57 among dogs that lived > 6 months compared to those who did not. Analysis of the TCGA 58 confirmed significant differences in survival among human sarcoma patients with high 59 and low expression of genes associated with greater immune activation and cytotoxicity 60 (CD3e, CD8a, IFN-γ, perforin, and CD122/IL-2 receptor beta). 61 62 Conclusions: Updated results from a first-in-dog clinical trial of palliative RT and 63 autologous NK cell immunotherapy for OSA illustrate the translational relevance of 64 companion dogs for novel cancer therapies. Similar to human studies, analyses of 65 immune markers from canine serum, PBMCs, and tumor tissue are feasible and provide 66 insight into potential biomarkers of response and resistance. 67 68
Introduction 72 73
Although approximately 60-70% of human patients with osteosarcoma (OSA) 74 treated with standard of care multimodality therapy experience long-term survival, these 75 numbers have remained static for the past three decades, and the survival of patients with 76 relapsed and/or metastatic OSA is dismal [1] [2] [3] . Despite evidence that OSA can be 77 recognized by the immune system [4] [5] [6] , the clinical experience with immunotherapy for 78 OSA has been disappointing. Moreover, evaluating and optimizing immunotherapy for an 79 orphan disease where up to 70% of patients experience long-term survival is challenging. 80 Indeed, poor compliance and retention in this patient population has been reported in the 81 recently completed worldwide EURAMOS trial [7] , clearly demonstrating the challenges 82 of evaluating immunotherapy in a disease with overall favorable, but variable outcomes. 83 84 Companion dog OSA demonstrates remarkable similarity to the complexity and 85 heterogeneity of human OSA [8, 9] . Importantly, unlike murine models of cancer based 86 on tumor injections and/or genetic-engineering, dogs develop spontaneous cancers in the 87 setting of an intact immune system, and naturally-occurring cancers in dogs recapitulate 88 the important host/tumor principles of immune equilibrium, immune evasion, and 89 immune escape [8, 10, 11] . In addition, the burden of dog cancer, including OSA, is 90 significant, and some investigators have estimated that the prevalence of cancer in 91 companion dogs is higher than that of humans [8] . Since there is a less established 92 standard of care in veterinary medicine, investigational treatments, such as 93 immunotherapy, can be considered earlier in the course of therapy, thereby allowing for 94 testing of novel therapies that can speed translation of innovative therapies to both dogs 95 and humans [11] . Taken together, dogs with naturally occurring cancer represent an ideal 96 model to evaluate novel immunotherapy approaches. Trials in companion animals are an 97 important bridge between pre-clinical testing in murine models and clinical trials in 98 people and allow for important proof-in-concept studies of innovative new strategies. 99 Concurrently, dog clinical trials provide key preliminary data on efficacy and toxicity in a 100 large animal model with notable similarity to people [11] . However, canine trials remain 101 nascent, and more studies are needed to underscore the generalizability of the findings, 102 the similarities of the immune readouts, and the validation of key reagents.
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Given our preliminary data showing that radiotherapy (RT) sensitizes tumors, 105 including sarcomas, to NK cytotoxicity as well as the unmet need for effective 106 immunotherapy in OSA [12], we previously conducted a clinical trial in dogs of palliative 107 RT plus intra-tumoral autologous NK transfer in dogs with non-metastatic OSA whose 108 owners elected not to pursue amputation or cytotoxic chemotherapy [13] . As part of this 109 clinical trial, we collected serial blood and tumor specimens pre-and post-treatment to 110 assess serum cytokines, to evaluate immune phenotype of circulating PBMCs, and to 111 analyze gene expression in tumor tissue. Our objective was to analyze blood and tissue 112 specimens as correlates of clinical response to NK/RT immunotherapy, and we 113 hypothesized that analysis of blood and tumor tissue would further validate the dog 114 model for canine immunotherapy studies and would provide preliminary evidence of 115 local or systemic immune response to treatment for testing in a larger trial. As our clinical 116 trial enrollment in dogs was small, we also queried The Cancer Genome Atlas (TCGA) to The schema of the enrollment, NK isolation and expansion, and radio-125 immunotherapy protocol have been described previously [13] . In brief, dogs were 126 considered eligible if they were diagnosed with locally advanced, non-metastatic OSA, 127 had adequate end organ function, and were not pursuing amputation or chemotherapy. 128 Our study enrollment was designed to accrue 10 patients in order to evaluate the primary 129 endpoint of lung metastasis formation at 6 months. The clinical trial was approved by the 130 UC Davis School of Veterinary Medicine Clinical Trials Review Board and the 131 Institutional Animal Care and Use Committee (protocol #18857).
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The clinical protocol consisted of 4 fractions of palliative RT at a dose of 9 Gy 134 weekly followed by two intra-tumoral injections of autologous canine NK cells (7.5 x 10 6 135 NK cells/kg) in 1-2 mL aliquots in sterile PBS during weeks 5 and 6 [13] . Recombinant 136 human IL-2 was co-injected with the NK cells at a dose of 250,000 IU/kg (Roche, NCI, 137 Frederick). Resting dog NK cells were isolated from a CD5 dim population, [14] but when 138 activated and mature were phenotyped as CD5-/CD3-/NKp46+. [15] We assessed for lung 139 metastasis using thoracic computed tomography every three months for the first six 140 months of follow-up followed by thoracic radiographs every three months thereafter. were diluted with staining buffer (2% FBS, 1 mM EDTA, and 0.02% NaN3 in PBS) and 171 blocking buffer using canine Fc receptor binding inhibitor (ThermoFisher, #14-9162-42) 172 and canine gamma globulin (Jackson ImmunoResearch, #004-000-002). Details 173 regarding specific antibodies utilized in this study can be found in Supplemental Table   174 2. For intracellular staining of canine interferon-γ and granzyme B, cells were mixed with 175 viability stain, then washed and incubated with fixation and permeabilization solution per 176 manufacturer's instructions (BD Biosciences). We then incubated with intracellular stain 177 or isotype prepared in Perm/Wash Buffer™ followed by centrifugation and resuspension Parametric continuous variables were compared using an independent samples t-test. 210 Non-parametric continuous variables were compared using the Mann-Whitney U test. For 211 comparison of more than two groups, statistical significance was determined using a one- PBMCs were isolated from trial subjects, and NK cells were isolated for 249 activation and expansion using CD5 depletion to enrich for the CD5 dim subset. As shown 250 in Figure 2A , pre-depletion PBMCs from trial subjects and healthy laboratory beagles We also assessed NK cytotoxic function in killing assays from selected time 276 points using both trial subjects and laboratory beagles. As shown in Figure 2C , after 17 - As shown in Figure 5 , we next evaluated the tumor microenvironment (TME) of 331 OSA in both untreated dogs and study subjects using immunohistochemistry and qRT-332 PCR. Lymph node tissue from a non-tumor bearing dog (Golden Retriever) and tumor 333 tissue from two soft tissue sarcoma and three OSA patients (all untreated and not study 334 patients) were evaluated for baseline lymphocyte infiltration (Figure 5A) . 335 Immunohistochemical analysis of these tumors revealed minimal CD3 infiltration in 336 untreated tumors compared to CD3-rich normal lymph node as a positive control. PCR 337 analysis of PBMCs (Figure 5A) from these same tumor-bearing, but non-study patients 338 showed a statistically greater expression of circulating CD3 transcripts compared to CD8 339 and NKG2D, and the expression of these transcripts in PBMCs was approximately 100-340 fold greater than the respective expression in OSA tumor tissue (P < 0.0001). In addition, 341 within OSA tumor tissue (Figure 5A) , the expression of the predominantly NK transcript 342 NKG2D was significantly lower than the expression of both CD3 and CD8 (P < 0.05). We then evaluated the expression of immune-related genes in matched biopsy 368 specimens from eight study dogs where pre-and post-treatment tumor tissue was 369 available before and after palliative RT and intra-tumoral NK. As shown in Figure 5B , 370 there was marked heterogeneity in the expression of immune-related genes after RT plus 371 NK transfer, both within and among patients. For example, two patients (patient 1 and 372 patient 8) showed notable increases in the expression of CD3 and CD8, while two 373 different patients showed greater than 10-fold increases in IL-6 expression. Patient 8 also 374 showed an approximately 40-fold increase in the expression of IDO1 (Figure 5B) . We survival. Similar to the levels of circulating IL-6, we did observe that study dogs who 379 died within 6 months appeared to have numerically greater (but not statistically different) 380 increases in intra-tumoral expression of IL-6 ( Figure 5G) , although the two patients with 381 elevated levels may represent outliers in an otherwise small sample size. However, 382 despite the lack of significant differences between survivors and non-survivors, these data 383 reinforce the validity of using these endpoints as hypothesis-generating data for 384 evaluation in future immunotherapy trials.
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The Cancer Genome Atlas were both associated with greater OS in human sarcomas (Figure 6 G -H) . Though limited in patient number, our results suggest that there may be a 453 predictive role for pre-treatment serum cytokines and intratumoral gene expression. 454 Specifically, this appears most prominent for pre-treatment serum IL-6, in which low 455 expression may correlate with improved survival and/or response to therapy. This 456 correlation with IL-6 is consistent with a large body of literature from human studies 457 suggesting that IL-6 adversely impacts cancer extent of disease and prognosis [23] . 458 Interestingly, however, analysis of TCGA data suggests that IL-6 and IL-6R expression 459 in the sarcoma TME may favorably impact OS. While our study does not answer these 460 critical questions regarding which immune genes and signatures reliably predict 461 prognosis and response to therapy, it does lends support to the validity of using the canine 462 model for more detailed immune dissection. As individual biomarkers often have limited 463 predictive value in larger data sets given the heterogeneity of human and dog patients, 464 immune signatures and gene clusters may prove to be more robust prognostic and 465 predictive tools, as was suggested by a recent multispecies analysis by Scott et al.[24] 466
